Pharma and profits : (Record no. 33453)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01349nam a2200169Ia 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260718102240.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 230508s2022 xx 000 0 und d |
| 050 ## - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | Allied HD 9666.4 |
| Item number | L36 2022 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | LaMattina, John L. |
| 245 10 - TITLE STATEMENT | |
| Title | Pharma and profits : |
| Remainder of title | balancing innovation, medicine, and drug prices / |
| Statement of responsibility, etc. | John L. LaMattina. |
| 264 ## - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Hoboken, NJ : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2022. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | xii, 100 pages ; |
| Dimensions | 23 cm. |
| 500 ## - GENERAL NOTE | |
| General note | Includes index. |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | ch. 1. The $1000 pill: the fiscal consequences of curing hepatitis C — ch. 2. Enter the players: FDA approval does not guarantee commercial success — ch. 3. Pandemic: mRNA vaccine and the race for a cure — ch. 4. Federal investment in r&d: why the government does not deserve a piece of biopharma’s profits? — ch. 5. Inaulin: the true cost of a 100-year-old drug — ch. 6. The costly alzheimer’s disease drug: a questionable breakthrough — ch. 7. Gene therapy: how much a life worth? — ch. 8. Proving the value of expensive drug: should we pay for drugs whose ultimate value is unknown? — cn. 9. Generic drugs: built-in cost controls — ch. 10. About those soaring pharma profits: are they driving healthcare costs? — ch. 11. Schemes to lower drug prices: the impact of reduced resources on r&d. |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Library of Congress Classification |
| Koha item type | Books |
| Call number prefix | EAC Cavite-Allied Health Sciences Section |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Shelving location | Date acquired | Cost, normal purchase price | Total Checkouts | Full call number | Barcode | Date last seen | Copy number | Price effective from | Koha item type | Cost, replacement price |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Library of Congress Classification | EAC Library Cavite | EAC Library Cavite | EAC Cavite-Allied Health Sciences Section | 05/16/2023 | 2695.50 | Allied HD 9666.4 L36 2022 | ML16622 | 05/29/2026 | c.1 | 05/16/2023 | Books | ||||||
| Library of Congress Classification | EAC Library Cavite | EAC Library Cavite | EAC Cavite-Allied Health Sciences Section | 11/20/2023 | 2695.50 | Allied HD 9666.4 L36 2022 c.2 | ML17504 | 05/29/2026 | c2 | 01/05/2024 | Books | 2695.50 |